Mangoceuticals Inc（MGRX）财务数据MGRXMangoceuticals Inc

Evaluating the bottom line, Mangoceuticals Inc maintains a gross margin of -342.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1909.52%, while the net margin is -1909.52%. These profitability ratios, combined with a Return on Equity (ROE) of -102.49%, provide a clear picture of how effectively MGRX converts its operational activities into shareholder value.

In the context of the broader market, MGRX competes directly with industry leaders such as SNGX and CNSP. With a market capitalization of $8.63M, it holds a significant position in the sector. When comparing efficiency, MGRX's gross margin of -342.77% stands against SNGX's N/A and CNSP's N/A. Such benchmarking helps identify whether Mangoceuticals Inc is trading at a premium or discount relative to its financial performance.

Mangoceuticals has shown fluctuating revenue with a total revenue of 68,757 USD in Q2 2026, but it continues to report significant net losses, including a net income of -1,312,653 USD in the same quarter. The gross margin is currently negative, indicating challenges in profitability.